AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03373032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
Study NCT03373032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up
Description: Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
Study NCT03373032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
Study NCT02275117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Study NCT02275117 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00858260 — intervention group
Intervention type: GENETIC
Intervention: blood sample
Description: Searching for Klotho variants in DNA
Study NCT01327274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Mini-Mover Procedure (Magnimplant)
Description: This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
Study NCT02376101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery less than 60 minutes
Study NCT02376101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery less than 60 minutes
Study NCT01693380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.
Study NCT01693380 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Control vaccine
Description: Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered.
Study NCT02577770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: therapeutic acupuncture treatment with actual needles
Study NCT02577770 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: therapeutic acupuncture treatment with actual needles
Study NCT02577770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg caffeine
Description: 8g coffee, po
Study NCT02577770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400mg caffeine
Description: 16g coffee, po
Study NCT02577770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated
Description: decaffeinated coffee, po
Study NCT01280539 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: 3 weeks, 5 times a week, 60 minutes a day.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine
Study NCT01280539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: 3 weeks, 5 times a week, 60 minutes a day.
Study NCT04053751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed suctioning system
Description: a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
Study NCT01420172 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
Study NCT00171925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
Study NCT00171925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium / Vitamin D
Description: Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
Study NCT02590562 — intervention group
Intervention type: OTHER
Intervention: Routine clinical practice
Study NCT03035253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-305B83
Study NCT03035253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
Study NCT03035253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
Study NCT04529369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle lobe only Photoselective vaporization of the prostate (PVP)
Description: Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
Study NCT04529369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete PVP
Description: Traditional Photoselective vaporization of the prostate PVP
Study NCT03153072 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Assess the absorption of oral amiodarone
Description: Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
Study NCT03538184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Preparation of implant beds entirely with piezo surgery implant tips
Study NCT03538184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drill
Description: Preparation of implant beds entirely with conventional implant drills
Study NCT04450628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeon unblinded
Description: The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication.
Study NCT04450628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP 1.0 System EF-100
Description: The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication.
Study NCT01158027 — intervention group
Intervention type: OTHER
Intervention: gait evaluation
Description: The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
Study NCT00481312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Continuous Infusion
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Memantine
Study NCT00481312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Continuous Infusion
Study NCT00824005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult stem cells
Description: Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
Study NCT00824005 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
Study NCT01510184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: Zevalin administered intravenous infusion.
Study NCT01510184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90-Zevalin
Description: Y-90-Zevalin administered by intravenous infusion.
Study NCT01510184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered by intravenous infusion.
Study NCT01510184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-111 Zevalin
Description: In-111-Zevalin administered by intravenously.
Study NCT03824275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- DCFPyL PET/CT
Description: A CT scan using a radioactive marker to better image tumors
Study NCT00304018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00304018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00304018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00304018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00304018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone
Study NCT00304018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00304018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT00304018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00304018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT04061954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive family intervention including individual sessions of FORNET
Description: Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided
Study NCT01943838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT01409083 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intravenous sodium bicarbonate
Description: Dilted sodium bicarbonate 2.1%
Study NCT01409083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous sodium bicarbonate
Description: Dilted sodium bicarbonate 2.1%
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Zopiclone
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam
Study NCT02614950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment interruption
Study NCT04225728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose IV
Description: Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14.
Study NCT04225728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric polymaltose hydroxide complex IM
Description: Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
Study NCT04225728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 100 ml i.v. of normal saline administered at Day 0 and at day 14.
Study NCT04458233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long axis FNA method
Description: ). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen
Study NCT01650233 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness-based stress reduction
Study NCT01650233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Study NCT01590238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRFM treatment
Description: Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
Study NCT02904473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GROWell
Description: The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
Study NCT02684266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
Study NCT06020365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sequential fecal microbiota transplant combined with small intestinal fluid transplant
Description: for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
Study NCT02384707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allegic food
Description: Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose
Study NCT02384707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00853125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
Study NCT00853125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
Study NCT03719404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium hypochlorite
Description: sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
Study NCT01958385 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Diet and Exercise
Description: A structured diet and exercise plan
Study NCT03719404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
Study NCT02599649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein every 4 weeks.
Study NCT02599649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
Study NCT02599649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 by vein for 7 days of a 28 day cycle.
Study NCT02408081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Nursing
Description: All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
Study NCT02498067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rPlan dual protection waiting room app intervention
Study NCT00780637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
Study NCT02185157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual -task exercises
Description: physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
Study NCT04034173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
Study NCT02185157 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic training
Description: The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
Study NCT04034173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
Study NCT04034173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid
Description: Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
Study NCT04034173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
Study NCT05683054 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels
Description: In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).